Trial Profile

A Phase 2 study of COYA 302 for the treatment of frontotemporal dementia

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 24 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Dec 2024 According to a Coya Therapeutics media release, topline results of a phase 1 COYA-302study in FTD will be leveraged to inform and finalize the planned trial design of a Company-sponsored, randomized, double-blinded Phase 2 trial of COYA 302 in patients with FTD.
19 Nov 2024 According to a Coya Therapeutics media release, company expect to see topline results in 2H 2025 from the investigator-initiated, open-label study of Low Dose IL-2 (LD IL-2) + CTLA4-Ig in FTD. The data are expected to guide this planned COYA 302 Phase 2 double-blind randomized study.
06 Nov 2024 According to a Coya Therapeutics media release, filing of IND for the COYA-302 Phase 2 trial in patients with FTD anticipated in 2H 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com